Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications by Richter, James M. et al.
Oral 5-Aminosalicylate, Mesalamine
Suppository, and Mesalamine Enema
as Initial Therapy for Ulcerative
Proctitis in Clinical Practice
with Quality of Care Implications
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Richter, James M., Nabeela K. Arshi, and Gerry Oster. 2016. “Oral 5-
Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema
as Initial Therapy for Ulcerative Proctitis in Clinical Practice with
Quality of Care Implications.” Canadian Journal of Gastroenterology
& Hepatology 2016 (1): 6928710. doi:10.1155/2016/6928710. http://
dx.doi.org/10.1155/2016/6928710.
Published Version doi:10.1155/2016/6928710
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662112
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Research Article
Oral 5-Aminosalicylate, Mesalamine Suppository, and
Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in
Clinical Practice with Quality of Care Implications
James M. Richter,1 Nabeela K. Arshi,2 and Gerry Oster2
1Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
2Policy Analysis Inc., Brookline, MA 02445, USA
Correspondence should be addressed to James M. Richter; jrichter@mgh.harvard.edu
Received 23 June 2015; Accepted 11 August 2015
Copyright © 2016 James M. Richter et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background.Ulcerative proctitis (UP) is typically treated initiallywith oral 5-aminosalicylate (“5-ASA”),mesalamine suppository, or
mesalamine enema (“UP Rx”). Little is known about their effectiveness in practice.Methods.Using a US health insurance database,
we identified new-onset UP patients between January 1, 2005, and December 31, 2007, based on the following: (1) initiation of
UP Rx; (2) endoscopy in prior 30 days resulting in diagnosis of UP; and (3) no prior encounters for ulcerative colitis or Crohn’s
disease. We examined the incidence of therapy escalation and total costs in relation to initial UP Rx. Results. We identified 548
patients: 327 received mesalamine suppository, 138 received oral 5-ASA, and 83 received mesalamine enema, as initial UP Rx.
One-third receiving oral 5-ASA experienced therapy escalation over 12 months, 21% for both mesalamine suppository and enema.
Mean cumulative total cost of UP Rx over 12 months was $1552, $996, and $986 for patients beginning therapy with oral 5-ASA,
mesalamine enema, and mesalamine suppository, respectively. Contrary to expert recommendations the treatments were often not
continued prophylactically. Conclusions. Treatment escalation was common, and total costs of therapy were higher, in patients who
initiated treatment with oral 5-ASA. Further study is necessary to assess the significance of these observations.
1. Introduction
Ulcerative colitis is a common chronic idiopathic inflamma-
tory disease of the colon, which causes diarrhea, bleeding,
and pain; its severity can range frommild to life-threatening.
Ulcerative colitis typically extends proximally in a circumfer-
ential and uninterrupted manner that involves either all or
only parts of the colon and sometimes is referred to with dif-
ferent terms, such as left-sided or pan colitis, depending upon
the degree of colonic involvement. In approximately 30% of
patients, the disease presents as ulcerative proctitis [1, 2] with
bowel inflammation limited to the rectum. Approximately
50% of patients with ulcerative proctitis have a relapsing-
remitting course that is characterized by flares of varying
severity and periods of remission during which patients
are relatively asymptomatic. During flares, patients typically
experience rectal bleeding, discomfort and urgency, pain,
passage of mucous, tenesmus, and diarrhea.
In general, treatment of ulcerative proctitis is determined
by the severity of symptoms and the extent of colonic involve-
ment [3–6]. Therapy is customarily tailored to the needs of
individual patients and is designed to reduce inflammation,
moderate symptoms, and maintain remission once achieved.
Treatment usually begins with oral mesalamine or rectally
administered (i.e., topical) mesalamine or glucocorticos-
teroids.
The efficacy of these drugs has been demonstrated in
randomized controlled trials. Most such studies, however, are
placebo-controlled and do not involve active comparators;
relatively little is therefore known about the comparative
effectiveness of drugs that form the cornerstone of the treat-
ment of ulcerative proctitis. Those few head-to-head clinical
trials that have been conducted point to possible differences
in effectiveness that may be important in clinical practice.
For example, a small randomized trial of oral versus rectal
mesalamine by Gionchetti and colleagues in 58 patients,
Hindawi Publishing Corporation
Canadian Journal of Gastroenterology and Hepatology
Volume 2016, Article ID 6928710, 7 pages
http://dx.doi.org/10.1155/2016/6928710
2 Canadian Journal of Gastroenterology and Hepatology
aged >18 years, with active, histologically confirmed ulcer-
ative proctitis, demonstrated the superiority of rectal drug
administration, in terms of improvement in mean Disease
Activity Index (DAI) score (𝑝 < 0.001), as well as the rate
of histologic remission (𝑝 < 0.01) [7]. A similar trial by
Kam and colleagues reported equivalent efficacy for oral
versus rectal administration of mesalamine in terms of the
primary efficacy outcome (DAI score), but rectal adminis-
tration reportedly was found to be superior on a number of
secondary efficacy endpoints, such as both physician-rated
and patient-rated global improvement. The percentage of
patients experiencing adverse events also was higher in the
oral mesalamine group [8]. Another trial by Biddle and col-
leagues found that the efficacy of oral and rectal mesalamine
did not differ but reported that combined treatment was
superior to either drug administered alone [9]. Because the
number of head-to-head comparisons of drug therapies for
the treatment of ulcerative proctitis is small, we undertook a
retrospective study to examine the comparative effectiveness
of oral 5-aminosalicylate (“oral 5-ASA”), mesalamine sup-
pository, andmesalamine enema as initial therapy in patients
newly presenting in clinical practice with ulcerative proctitis.
2. Materials and Methods
2.1. Data Source. This study used data from a large, United
States based private health insurance claims database,Thom-
son ReutersMarketScan Commercial Claims and Encounters
and Medicare Supplemental and Coordination of Benefits
Database (“MarketScan database”), spanning the period of
January 1, 2004, through December 31, 2008. The database
consists of information from employer-sponsored insurance
plans throughout the US providing health benefits to over 15
million persons annually, including employees, their spouses,
and their dependents.
Data available for each facility and professional-service
claim include date and place of service, diagnoses, proce-
dures performed/services rendered, and quantity of services
(professional-service claims). Data available for each retail
pharmacy claim include the drug dispensed, dispensing date,
quantity dispensed, and number of therapy days supplied.
Selected demographic and insurance eligibility information
is also available for persons in the database, including age,
sex, geographic location, coverage type, and the beginning
and end (if relevant) of health insurance coverage. All claims
include paid (i.e., reimbursed) amounts, including patient
deductibles, copays, and/or coinsurance amounts. Patient-
level data can be arrayed chronologically to provide a detailed
longitudinal profile of all medical and pharmacy services
used by each plan member.
2.2. Sample Selection. We identified all persons in the study
database aged ≥18 years who underwent colonoscopy or
sigmoidoscopy leading to a diagnosis of ulcerative proctitis
(ICD-9-CM 556.2) or ulcerative proctosigmoiditis (556.3)
between January 1, 2005, and December 31, 2007. Among
these persons, we identified those who also had evidence
of receipt of an oral 5-ASA (balsalazide, oral mesalamine
(e.g., Asacol, Pentasa, and Rowasa), and sulfasalazine),
mesalamine suppository (Canasa), or mesalamine enema
(e.g., Rowasa) (“UP-related medications”) within 30 days of
the procedure. Date of initial receipt of UP-related medica-
tion was designated the “index date.”
We excluded patients with (1) less than 12 months of
complete encounter data prior to and following their index
date (i.e., 24 months in total); (2) evidence of receipt of 5-
ASA, metronidazole, antimetabolite, glucocorticoid, or TNF
inhibitor within 365 days prior to their index date; (3)
any medical encounters with a primary diagnosis code of
ulcerative colitis (ICD-9-CM 556.X, excluding 556.2 and
556.3) and/or Crohn’s disease (ICD-9-CM 555.X or 556.X) in
the period beginning 365 days prior to index date and ending
31 days prior to index date; or (4) evidence of receipt of more
than one UP-related medication on their index date. We then
stratified patients into three mutually exclusive treatment
groups, based on the therapy received on the index date, as
follows: (1) oral 5-ASA; (2) mesalamine suppository; or (3)
mesalamine enema.
2.3. Measures and Analyses. We examined the baseline char-
acteristics of patients in each treatment group, including
age, gender, geographic location, principal payer, and ther-
apy days dispensed on the index date. Comorbidities were
assessed based on a scan of all ICD-9-CM diagnosis codes
in the one-year period preceding the index date.
Measures that we examined over the one-year period
following each patient’s index date included the following:
(1) receipt of any othermedication for the treatment of inflam-
matory bowel disease (IBD) (e.g., corticosteroids, immuno-
modulators, and biologic response modifiers) (“treatment
escalation”); (2) hospitalization and emergency department
encounters for the treatment of IBD; and (3) total costs of
pharmacotherapy for IBD. Each of these measures was exam-
ined on a cumulative basis, beginning with the index date. All
analyses were descriptive in nature, and significance testing
was not performed, as there were no a priori hypotheses. All
costs are expressed in United States dollars.
3. Ethical Considerations
All Protected Health Information (as defined by the Health
Insurance Portability and Accountability Act of 1996 and
federal guidance on Public Welfare and the Protection of
Human Subjects) was either removed from the database or
encrypted, rendering it a “limited dataset” containing only
“deidentified” information, as defined by relevant legislation
and regulation [10, 11]. Institutional Review Board (IRB)
review was not needed for this study, per the Code of Federal
Regulations, since “. . .subjects cannot be identified, directly
or through identifiers linked to the subjects. . .” [11].
4. Results
4.1. Patient Characteristics. We identified a total of 548
patients who met all study entry criteria; 145 patients were
excluded due to evidence of receipt of >1 UP-related med-
ication on index date (Table 1). Patient mean (±SD) age
was 47.3 (±15.6) years, and the number of men and women
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Table 1: Selection of study subjects with newly diagnosed ulcerative proctitis.
Criterion Total patients
Patients aged ≥18 years who underwent colonoscopy/sigmoidoscopy between January 1, 2005, and
December 31, 2007, resulting in a diagnosis of ulcerative proctitis (ICD-9-CM 556.2) or ulcerative
proctosigmoiditis (556.3)
11,475
Evidence of receipt of a 5-ASA (oral, enema, or suppository) within 30 days of this procedure
(date of first receipt termed “index date”)
2587
≥12 months of complete encounter data before and after index date 1401
No evidence of receipt of a 5-ASA, metronidazole, antimetabolite, glucocorticoid, or TNF
inhibitor in the 365 days preceding index date
743
No medical encounters with a primary diagnosis code for ulcerative colitis (ICD-9-CM 556.X,
excluding 556.2 and 556.3) and/or Crohn’s disease (ICD-9-CM 555.X or 556.X) 31 to 365 days
prior to index date
693
No evidence of receipt of >1 UP-related medication on index date 548
UP: ulcerative proctitis.
was approximately equal. More than 40 percent of study
subjects were from the South (US), and over one-half (54.4%)
had health insurance coverage characterized by a preferred
provider organization. Hypertension, diabetes, and heart
disease were frequently noted comorbidities, based on a scan
of ICD-9-CM diagnosis codes in the year prior to index date
(Table 2). The most frequently prescribed initial therapy was
mesalamine suppository (59.7% of study subjects), followed
by oral 5-ASA (25.2%) and mesalamine enema (15.1%).
4.2. Treatment Escalation. The percentage of patients who
experienced treatment escalation (i.e., began therapy with
another medication for IBD, such as a corticosteroid,
immunomodulator, or biologic response modifier) was con-
sistently higher among those who received oral 5-ASA on
their index date in comparison with those who received
mesalamine suppository ormesalamine enema as their initial
therapy (Figure 1). At one year, 34.1% of patients who initiated
treatment with oral 5-ASA had evidence of receipt of another
agent, versus 20.8% and 20.5% of patients who received
mesalamine suppository or mesalamine enema, respectively,
on their index date (Table 3).
4.3. Hospitalizations and Emergency Department Visits. Very
few patients were hospitalized for the treatment of IBD over
the one-year period of follow-up (Table 4); rates of emergency
department encounters also were low (Table 5). No patients
underwent surgery for IBD during this 12-month period.
4.4. Cost of Pharmacotherapy. Mean cumulative cost per
patient of pharmacotherapy for the treatment of IBD
increased over time in all three treatment groups. At one
year, mean cumulative cost of pharmacotherapy for IBD in
patients who began treatment with oral 5-ASA averaged
$1552; for patients initiating treatment with mesalamine
enema, mean cumulative cost was $995; and for those who
received mesalamine suppository on their index date, mean
cumulative cost per patient was $986 (Table 6).There were no
meaningful differences in total costs among the three groups.
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Figure 1: Cumulative percentage of study subjects experiencing
treatment escalation, by duration of follow-up and treatment group.
Oral 5-ASA: oral 5-aminosalicylate.
4.5. Quality of Care Implications. Among the patients with
ulcerative proctitis beginning therapy with a mesalamine
suppository, approximately 70% discontinued such treatment
within one month; about 20% of these patients, however, had
evidence of continued receipt of mesalamine suppositories
throughout the year. While adjunctive use of oral medica-
tions, mainly, oral 5-ASAs, was low initially (4%), it increased
steadily over the year.
5. Discussion
Treatment of ulcerative proctitis usually begins with oral
mesalamine or rectally administered (i.e., topical) mesala-
mine or glucocorticosteroids. Although the efficacy of these
drugs has beendemonstrated in randomized controlled trials,
they rarely have been compared on a head-to-head basis, and
evidence of their comparative effectiveness is therefore lim-
ited. To shed light on this issue, we undertook a retrospective
study of the effectiveness of oral 5-ASA, mesalamine suppos-
itory, and mesalamine enema as initial therapy in patients
newly presenting in clinical practice with ulcerative proctitis.
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Table 2: Baseline characteristics of study subjects with ulcerative proctitis (𝑁 = 548), by treatment group.
Characteristic
Treatment group
Total
(𝑁 = 548)Oral 5-ASA(𝑛 = 138)
Mesalamine
suppository
(𝑛 = 327)
Mesalamine
enema
(𝑛 = 83)
Age, years
Mean (SD) 51.3 (16.1) 45.5 (15.3) 47.5 (14.9) 47.3 (15.6)
Median 51 45 45 47
Minimum 20 18 18 18
Maximum 89 89 86 89
Frequency distribution by age group, years, 𝑛 (%)
18–24 7 (5.1) 28 (8.6) 5 (6.0) 40 (7.3)
25–34 14 (10.1) 55 (16.8) 12 (14.5) 81 (14.8)
35–44 29 (21.0) 75 (22.9) 22 (26.5) 126 (23.0)
45–54 33 (23.9) 78 (23.9) 17 (20.5) 128 (23.4)
55–64 29 (21.0) 60 (18.3) 15 (18.1) 104 (19.0)
65–74 12 (8.7) 17 (5.2) 7 (8.4) 36 (6.6)
75–84 9 (6.5) 11 (3.4) 4 (4.8) 24 (4.4)
85–94 5 (3.6) 3 (0.9) 1 (1.2) 9 (1.6)
Gender, 𝑛 (%)
Male 77 (55.8) 136 (41.6) 39 (47.0) 252 (46.0)
Female 61 (44.2) 191 (58.4) 44 (53.0) 296 (54.0)
Geographic location, 𝑛 (%)
Northeast 17 (12.3) 42 (12.8) 13 (15.7) 72 (13.1)
North central 49 (35.5) 93 (28.4) 20 (24.1) 162 (29.6)
South 45 (32.6) 145 (44.3) 35 (42.2) 225 (41.1)
West 26 (18.8) 45 (13.8) 15 (18.1) 86 (15.7)
Unknown 1 (0.7) 2 (0.6) 0 (0.0) 3 (0.5)
Principal payer, 𝑛 (%)
Basic/major medical 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Comprehensive 30 (21.7) 42 (12.8) 13 (15.7) 85 (15.5)
HMO 19 (13.8) 53 (16.2) 11 (13.3) 83 (15.1)
POS, POS with capitation 12 (8.7) 43 (13.1) 11 (13.3) 66 (12.0)
PPO 74 (53.6) 178 (54.4) 46 (55.4) 298 (54.4)
Other 3 (2.2) 11 (3.4) 2 (2.4) 16 (2.9)
Therapy days dispensed on index date, 𝑛 (%)
Oral 5-ASA 31 (15.2) 0 (0.0) 0 (0.0) 8 (15.6)
Mesalamine suppository 0 (0.0) 27 (9.0) 0 (0.0) 16 (14.8)
Mesalamine enema 0 (0.0) 0 (0.0) 22 (8.0) 3 (8.6)
Comorbidities (ICD-9-CM), 𝑛 (%)
Colorectal comorbidities (ICD-9-CM)
Abscess of anal and rectal regions (566) 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.2)
Anal fissure and fistula (565) 3 (2.2) 4 (1.2) 2 (2.4) 9 (1.6)
Benign tumor of the colon (211.3) 15 (10.9) 24 (7.3) 9 (10.8) 48 (8.8)
Benign tumor of the rectum and anal canal (211.4) 1 (0.7) 5 (1.5) 1 (1.2) 7 (1.3)
Diverticula of intestine (562) 10 (7.2) 12 (3.7) 6 (7.2) 28 (5.1)
Functional digestive disorders, not elsewhere classified (564) 15 (10.9) 36 (11.0) 6 (7.2) 57 (10.4)
Malignant neoplasm of colon (153) 0 (0.0) 0 (0.0) 1 (1.2) 1 (0.2)
Canadian Journal of Gastroenterology and Hepatology 5
Table 2: Continued.
Characteristic
Treatment group
Total
(𝑁 = 548)Oral 5-ASA
(𝑛 = 138)
Mesalamine
suppository
(𝑛 = 327)
Mesalamine
enema
(𝑛 = 83)
Other and unspecified noninfectious gastroenteritis and colitis
(558) 54 (39.1) 56 (17.1) 25 (30.1) 135 (24.6)
Vascular insufficiency of intestine (557) 2 (1.4) 0 (0.0) 0 (0.0) 2 (0.4)
Other digestive comorbidities (ICD-9-CM)
Chronic liver disease and cirrhosis (571) 1 (0.7) 2 (0.6) 1 (1.2) 4 (0.7)
Diseases of esophagus (530) 13 (9.4) 30 (9.2) 9 (10.8) 52 (9.5)
Disease of pancreas (577) 0 (0.0) 2 (0.6) 0 (0.0) 2 (0.4)
Duodenal ulcer (532) 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.2)
Gastric ulcer (531) 0 (0.0) 1 (0.3) 1 (1.2) 2 (0.4)
Common nondigestive comorbidities (ICD-9-CM)
Asthma (493) 5 (3.6) 7 (2.1) 2 (2.4) 14 (2.6)
Atherosclerosis (440) 1 (0.7) 2 (0.6) 0 (0.0) 3 (0.5)
Chronic bronchitis (491) 2 (1.4) 0 (0.0) 0 (0.0) 2 (0.4)
Diabetes mellitus (250) 15 (10.9) 16 (4.9) 6 (7.2) 37 (6.8)
Essential hypertension (401) 29 (21.0) 52 (15.9) 17 (20.5) 98 (17.9)
Iron deficiency anemias (280) 10 (7.2) 5 (1.5) 2 (2.4) 17 (3.1)
Ischemic heart disease (410–414) 13 (9.4) 12 (3.7) 4 (4.8) 29 (5.3)
HMO: health maintenance organization.
Oral 5-ASA: oral 5-aminosalicylate.
POS: point of service.
PPO: preferred provider organization.
Table 3: Cumulative number of study subjects experiencing treatment escalation, by duration of follow-up and treatment group.
Treatment
group
Month 3 Month 6 Month 9 Month 12
𝑛 (%) 95% CI (%) 𝑛 (%) 95% CI (%) 𝑛 (%) 95% CI (%) 𝑛 (%) 95% CI (%)
Oral 5-ASA
(𝑛 = 138) 29 (21.0) (14.2, 27.8) 37 (26.8) (19.4, 34.2) 42 (30.4) (0.3, 22.8) 47 (34.1) (26.2, 42.0)
Mesalamine
suppository
(𝑛 = 327)
31 (9.5) (6.3, 12.7) 52 (15.9) (11.9, 19.9) 59 (18.0) (0.2, 13.9) 68 (20.8) (16.4, 25.2)
Mesalamine
enema
(𝑛 = 83)
10 (12.0) (5.0, 19.1) 15 (18.1) (9.8, 26.4) 17 (20.5) (0.2, 11.8) 17 (20.5) (11.8, 29.2)
Oral 5-ASA: oral 5-aminosalicylate.
Table 4: Cumulative incidence of hospitalization for inflammatory bowel disease, by treatment group and duration of follow-up.
Treatment group Month 3
𝑛 (%)
Month 6
𝑛 (%)
Month 9
𝑛 (%)
Month 12
𝑛 (%)
Oral 5-ASA (𝑛 = 138) 3 (2.2) 4 (2.9) 4 (2.9) 5 (3.6)
Mesalamine suppository (𝑛 = 327) 4 (1.2) 5 (1.5) 5 (1.5) 6 (1.8)
Mesalamine enema (𝑛 = 83) 1 (1.2) 1 (1.2) 2 (2.4) 2 (2.4)
Oral 5-ASA: oral 5-aminosalicylate.
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Table 5: Cumulative incidence of emergency department visits for inflammatory bowel disease, by treatment group and duration of follow-up.
Treatment group Month 3
𝑛 (%)
Month 6
𝑛 (%)
Month 9
𝑛 (%)
Month 12
𝑛 (%)
Oral 5-ASA (𝑛 = 138) 1 (0.7) 1 (0.7) 1 (0.7) 1 (0.7)
Mesalamine suppository (𝑛 = 327) 3 (0.9) 4 (1.2) 4 (1.2) 6 (1.8)
Mesalamine enema (𝑛 = 83) 0 (0.0) 1 (1.2) 2 (2.4) 2 (2.4)
Oral 5-ASA: oral 5-aminosalicylate.
Table 6: Cumulative total per-patient cost (in USD) of pharmacotherapy related to inflammatory bowel disease, by treatment group and
duration of follow-up.
Treatment group Month 3Mean $ (SD)
Month 6
Mean $ (SD)
Month 9
Mean $ (SD)
Month 12
Mean $ (SD)
Oral 5-ASA (𝑛 = 138) 589 (424) 926 (699) 1,251 (1,089) 1,552 (1,418)
Mesalamine suppository (𝑛 = 327) 460 (330) 663 (607) 815 (829) 986 (1,095)
Mesalamine enema (𝑛 = 83) 514 (369) 646 (596) 850 (929) 995 (1,172)
Oral 5-ASA: oral 5-aminosalicylate.
Our findings confirm the relatively favorable natural
history of distal colitis in a large community-based cohort
of patients with newly presenting disease who were followed
up for one year. There were few hospitalizations, and no one
required surgery or was treated with a biological agent. Our
results also confirm the observation that topical or rectal
mesalamine may be superior to oral mesalamine. Although
we measured treatment escalation rather than response to
treatment, which is the more commonly studied outcome,
it is a complementary endpoint [12]. Treatment escalation
in clinical practice represents the active judgment of the
treating physician that prior treatment was unsatisfactory.
We could not determine if the treatment escalation was
due to disease extension. In addition, it is a comparison of
treatment options, rather than a comparison of a treatment to
placebo, and addresses the relevant question of comparative
effectiveness of treatments that practicing clinicians confront.
Interestingly, despite our results and previous studies
demonstrating the superiority of topical mesalamine for
patients with limited disease, the frequency of prescribing
oral mesalamine increased sixfold between 1992 and 2009,
while the frequency of prescribing topical preparations was
almost unchanged [13]. Nevertheless, the majority of patients
with ulcerative proctitis in our study were treated with topical
drugs. To the best of our knowledge, our study is the first to
utilize health insurance claims data, and our results suggest
that topical therapymay be less costly andmore effective than
the other treatment options studied.
The American College of Gastroenterology and the
Toronto Consensus recommend that 5-ASA preparations be
used as initial treatment for patients with mild to moderate
disease and for the prevention of relapse; in patients with dis-
ease confined to the rectosigmoid area, topical preparations
may be useful [3, 14]. The failure to continue treatment for
prevention represents a deviation from recommendations,
might lead to later escalation, and deserves further study.The
relative convenience, acceptability of, and compliance with
oral versus rectal dosing have not been systematically studied.
We did not directly measure compliance in our study, but
claims data are based on dispensed prescriptions rather than
physician orders, and the former may serve as a proxy for
treatment compliance. One hundred forty-five patients were
treated with combinations that prevented us from studying
those subgroups; findings from work by Safdi and colleagues
suggest that treatment with the combination of oral and rectal
mesalamine therapy may provide faster and more complete
symptom relief than either therapy alone [15].
We note a number of limitations of our study. As with all
studies based on administrative databases, errors of commis-
sion and omission are always a concern, especially regarding
the ascertainment of medical conditions using ICD-9-CM
diagnosis codes. The sensitivity and specificity of such codes
in correctly identifying patients with IBD were recently
reported to be 84% and 99%, respectively [16]. We also note
that since data were left-censored 12 months prior to index
date, our study population probably consisted of patients
with true incident cases as well as those experiencing recur-
rence of their disease. This could also potentially serve as
an explanation for some of the colorectal and digestive
comorbidities recorded at baseline and could introduce selec-
tion bias—specifically, lead-time bias—since comparisons
between patients and treatment groups would no longer be
based on the same point in the course of disease. Additionally,
our analysis may not be representative of the entire popula-
tion of patients with ulcerative proctitis, due to the under-
representation of older Medicare patients in our database
and the exclusion of children. Next, although we examined
some baseline characteristics, theremay be inherent, unnoted
differences (e.g., lifestyle and diet) between patients in the
three treatment groups or between the types of disease (e.g.,
proctitis and proctosigmoiditis) that patients experienced
in each treatment group, which may affect outcomes. The
impact of the treatments on recurrence rates, disease progres-
sion, or the need for prophylactic treatment is also unknown
and was not determined in our analyses. Similarly, the data
do not provide insight into patient treatment adherence or
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reasons for treatment escalation, which may or may not
be related to the initial therapy itself. Finally, the lack of
significance testing means that we cannot make definitive
statements about the significance of differences between
treatment groups.
In summary, our study suggests that treatment escalation
may occur more frequently among patients with new-onset
ulcerative proctitis who initiate treatment with oral 5-ASA
rather than mesalamine suppository or mesalamine enema.
Total costs of pharmacotherapy alsomay be higher in patients
receiving oral 5-ASA as initial therapy. Further study is
necessary to assess the significance of these observations.
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